Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

PE-22-28 Dosage Protocol | PeptideDosages.com

PE-22-28 (10 mg Vial) Dosage Protocol PE-22-28 Dosage Chart PE-22-28 is dosed at 50 mcg–200 mcg daily via subcutaneous injection in educational protocols. A 10 mg vial reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for res

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

PE-22-28 (10 mg Vial) Dosage Protocol

PE-22-28 Dosage Chart

PE-22-28 is dosed at 50 mcg–200 mcg daily via subcutaneous injection in educational protocols. A 10 mg vial reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.

Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.

Typical daily range: 50–200 µg once daily (gradual titration over 8–16 weeks).

Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 µg on a U-100 insulin syringe.

Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); protect from light.

PE-22-28 is a synthetic heptapeptide (sequence: GVSWGLR) derived from the sortilin propeptide, engineered as a potent and selective antagonist of TREK-1 potassium channels[4]. Preclinical studies demonstrate rapid antidepressant-like effects, enhanced neurogenesis, and neuroprotection with a favorable safety profile showing no cardiac or metabolic side effects[2][3]. This educational protocol presents a once-daily subcutaneous approach with gradual titration.

Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read PE-22-28 Peptide: Benefits, Uses, Side Effects, Dosage, and Research.

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Weeks 1–2

50 µg

1.5 units (0.015 mL)

Weeks 3–4

100 µg

3 units (0.03 mL)

Weeks 5–8

Weeks 9–12 (Optional)

150 µg

4.5 units (0.045 mL)

Weeks 13–16 (Optional)

200 µg

6 units (0.06 mL)

Frequency: Inject once daily subcutaneously. This schedule uses a practical 3.0 mL dilution for accurate measurement. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability. Many researchers find 100–150 µg sufficient given PE-22-28’s high potency[4].

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.

Inject slowly down the vial wall; avoid foaming.

Gently swirl/roll until dissolved (do not shake).

Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration. Replace vials every 4 weeks to maintain potency.

Peptide Vials (PE-22-28, 10 mg each):

8 weeks ≈ 2 vials

12 weeks ≈ 3 vials

16 weeks ≈ 4 vials

Insulin Syringes (U-100):

Per week: 7 syringes (1/day)

8 weeks: 56 syringes

12 weeks: 84 syringes

16 weeks: 112 syringes

Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.

8 weeks (2 vials): 6 mL → 1 × 10 mL bottle

12 weeks (3 vials): 9 mL → 1 × 10 mL bottle

16 weeks (4 vials): 12 mL → 2 × 10 mL bottles

Alcohol Swabs: One for the vial stopper + one for the injection site each day.

Per week: 14 swabs (2/day)

8 weeks: 112 swabs → recommend 2 × 100-count boxes

12 weeks: 168 swabs → recommend 2 × 100-count boxes

16 weeks: 224 swabs → recommend 3 × 100-count boxes

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Frequently Asked Questions About PE-22-28

Straight answers on reconstitution, dosing, and safety, everything you need to research with confidence. For research reference only.

Source: peptidemind.com ↗
02What If I Reconstituted with 2mL but Only Have 1.8mL of Bacteriostatic Water in the Vial?

Some volume loss during transfer is normal due to needle dead space and vial surface tension. Use the actual volume you added. 1.8mL. For your concentration calculation, not the intended 2mL. A 5mg vial with 1.8mL yields 5mg ÷ 1.8mL = 2.78mg/mL (2,778mcg/mL). For a 250mcg dose: 250 ÷ 2,778 = 0.09mL or 9 units. Precision matters. Assuming 2mL when you actually added 1.8mL creates a 10% dosing error across the entire vial.

Source: realpeptides.co ↗
03What If My Reconstituted Vial Was Left at Room Temperature Overnight?

Discard the vial. Do not attempt to salvage it by re-refrigerating. Peptide aggregation begins within 4–6 hours at 20–25°C and accelerates exponentially beyond that point. The aggregates are irreversible; cooling them does not restore bioactivity. Visual clarity is not a reliable indicator. Aggregated peptides often remain visually clear while being pharmacologically inert. The financial loss of one vial is preferable to 28 days of ineffective dosing and confounded research outcomes.

Source: realpeptides.co ↗
04Davunetide — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Davunetide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
05Amycretin — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Amycretin is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
Research context

Read sources and limitations before applying a claim.

Small-Batch SNAP-8 Research Calculations

A typical 30 g or 50 g topical batch requires a measured portion of the vial to match the 0.0015% to 0.005% active reference range. 0.45 mg 0.90 mg 1.50 mg 0.75 mg 2.50 mg 3.00 mg 5.00 mg 6.00 mg 10.00 mg Formula: Peptide mg needed = target percent multiplied by final batch grams multiplied by 10.

Source: peptidedosages.com ↗

Why AHK-Cu draws research interest

These are the directions researchers and the peptide community most often explore AHK-Cu for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.

Source: dosagepeptide.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Potential benefits

Potential Benefits & Side Effects

Observations from preclinical and early research literature. May support reductions in fat mass while preserving lean muscle in animal models[8][9]. Associated with elevated NAD+ levels and SIRT1 activation in preclinical studies[2][3]. Enhanced grip strength observed in aged mice when combined with exercise[10]. Generally well tolerated; occasional reports of mild headache, transient jitteriness, or injection-site reactions. Long-term human safety data not established; this compound remains investigational.

Source: peptidedosages.com ↗
Side effects

Common Side Effects

▪Unknown in humans — this is the honest headline. With no human study of any kind, P21 has no characterized human side-effect profile, no known interactions and no established contraindications. Absence of reported harm is not evidence of safety; it is absence of data. ▪Proliferation is the theoretical concern: A compound whose stated purpose is driving cell proliferation and survival invites the obvious question about unwanted growth. The reassuring datum is that ~2 years of continuous oral dosing produced no tumors in mice[1]. The limit of that datum is that a rodent lifespan study in a specific transgenic line cannot settle the question for humans. ▪The parent molecule was poorly tolerated: CNTF itself caused anorexia, severe cramps and muscle pain in trials — which is why the epitope approach exists. P021 showed none of these in mice[1], but the family history is a reason for caution rather than confidence. ▪Injection-site and sterility risks apply as always: Any self-prepared subcutaneous injection carries risks of injection-site reaction, contamination and dosing error — and unlike an approved drug, research-grade material has no regulated identity, purity or endotoxin standard behind it.

Source: dosagepeptide.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →